N,N-Dimethyl-5-[(4-Phenylphenyl)Methyl]Tetrazole-1-Carboxamide 5-([1,1’-联苯]-4-甲基)-N,N-二甲基-1H-四氮唑-1-甲酰胺
CAS 874902-19-9 MFCD08703123
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Approved Therapeutics/Drug Candidates, Cannabinoids, Cell Biology, Cell Signaling and Neuroscience, Eli Lilly, Neurobiology, Neuroscience, Pharmacologicals
相关文献及参考
- [2]. Sun L, et al. Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation. Eur J Pain. 2017 May;21(5):804-814.
- [3]. Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc. 2006 Aug 2;128(30):9699-704.
- [4]. Maione S, et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br J Pharmacol. 2008 Nov;155(5):775-82.
- [5]. Pelorosso FG, et al. The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein. Eur J Pharmacol. 2009 Jan 5;602(1):176-9.
- [6]. Powers MS, et al. Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking
安全信息
GHS Symbol
- H302 Harmful if swallowed 吞食有害
- R22 Harmful if swallowed 吞咽有害